Phaseline

Companies › Zogenix

Zogenix: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 4, 1 Phase 3, 1 Phase 2; Neurology; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Fenfluramine
Serotonin 1d (5-HT1d) receptor agonist; Serotonin 2c (5-HT2c) receptor agonist; Sigma opioid receptor antagonist
HTR1D, HTR2C, SIGMAR1Phase 3CDKL5 Deficiency Disorder; Dravet Syndrome (DS); Dravet Syndrome; Infantile SpasmNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06598449FenfluraminePhase 4Dravet Syndrome (DS)NeurologyDec 2026
NCT04289467FenfluraminePhase 2Infantile SpasmNeurologyDec 2026
NCT07112365FenfluraminePhase 4Dravet SyndromeNeurologySep 2027
NCT05064878FenfluraminePhase 3CDKL5 Deficiency DisorderNeurologyNov 2027

Targets

HTR1D (1) HTR2C (1) SIGMAR1 (1)

Companies with the same targets

UCB BIOSCIENCES Exciva Technophage Boryung Pharmaceutical Tonix Pharmaceuticals Anavex Life Sciences Pentixapharm CSPC Ouyi Pharmaceutical

Companies built like this

Bigespas JYAMS PET Research & Development Longboard Pharmaceuticals TriGemX Bio ML Bio Solutions

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.